TY - JOUR
T1 - Cost-effectiveness of blood culture and a multiplex real-time PCR in hematological patients with suspected sepsis
T2 - An observational propensity score-matched study
AU - Mancini, Nicasio
AU - Sambri, Vittorio
AU - Corti, Consuelo
AU - Ghidoli, Nadia
AU - Tolomelli, Giulia
AU - Paolucci, Michela
AU - Clerici, Daniela
AU - Carletti, Silvia
AU - Greco, Raffaella
AU - Tassara, Michela
AU - Pizzorno, Beatrice
AU - Zaniolo, Orietta
AU - Povero, Massimiliano
AU - Pradelli, Lorenzo
AU - Burioni, Roberto
AU - Stanzani, Marta
AU - Landini, Maria Paola
AU - Ciceri, Fabio
AU - Clementi, Massimo
PY - 2014
Y1 - 2014
N2 - We evaluated the costs and clinical outcomes of episodes of suspected sepsis in hematological patients. A propensity score-matched study was planned, comparing a retrospective cohort managed with standard assays and a prospective cohort managed with the addition of a molecular assay. Diagnostic procedures and therapy were considered as costs variables. The primary clinical endpoint was sepsis-related mortality, whereas the length of each suspected sepsis episode was investigated as a secondary endpoint. A total of 137 and 138 episodes in the prospective and the retrospective cohorts were studied, respectively; 101 pairs of highly matched episodes were analyzed, evidencing a trend of higher mortality in the retrospective cohort. No difference in length of suspected sepsis episode was observed. Significant savings were observed in the prospective cohort, especially due to reduced costs in antifungal therapy. The apparently more expensive molecular assay favored a more rational use of economic resources without influencing, and probably improving, the clinical outcome.
AB - We evaluated the costs and clinical outcomes of episodes of suspected sepsis in hematological patients. A propensity score-matched study was planned, comparing a retrospective cohort managed with standard assays and a prospective cohort managed with the addition of a molecular assay. Diagnostic procedures and therapy were considered as costs variables. The primary clinical endpoint was sepsis-related mortality, whereas the length of each suspected sepsis episode was investigated as a secondary endpoint. A total of 137 and 138 episodes in the prospective and the retrospective cohorts were studied, respectively; 101 pairs of highly matched episodes were analyzed, evidencing a trend of higher mortality in the retrospective cohort. No difference in length of suspected sepsis episode was observed. Significant savings were observed in the prospective cohort, especially due to reduced costs in antifungal therapy. The apparently more expensive molecular assay favored a more rational use of economic resources without influencing, and probably improving, the clinical outcome.
KW - Sepsis
UR - http://www.scopus.com/inward/record.url?scp=84901266851&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901266851&partnerID=8YFLogxK
U2 - 10.1586/14737159.2014.916212
DO - 10.1586/14737159.2014.916212
M3 - Article
C2 - 24844138
AN - SCOPUS:84901266851
VL - 14
SP - 623
EP - 632
JO - Expert Review of Molecular Diagnostics
JF - Expert Review of Molecular Diagnostics
SN - 1473-7159
IS - 5
ER -